Jayne M. Munger

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Cooley advised Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, on its upsized $1 billion aggregate principal amount of 0% convertible senior notes due 2029, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $130 million aggregate principal amount of notes, a figure comprising an initial $870 million aggregate principal amount of notes and the exercise in full of the initial purchasers’ option to purchase up to an additional $130 million aggregate principal amount.

Cooley advised Core Scientific (NASDAQ: CORZ), a leader in digital infrastructure for bitcoin mining and high-performance computing, on its $625 million aggregate principal of 0.00% convertible senior notes due 2031, which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of notes.

Cooley advised Sword Health, pioneer of the AI Care platform, which uses artificial intelligence to power the delivery of care, on its raise of $130 million in a mix of primary and secondary sales.

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.